中国药房2026，Vol.37Issue(2)：142-148,7.DOI:10.6039/j.issn.1001-0408.2026.02.02
我国5种上市血小板生成素受体激动剂的临床综合评价
Clinical comprehensive evaluation of five marketed thrombopoietin receptor agonists in China
摘要
Abstract
OBJECTIVE To conduct a clinical comprehensive evaluation of five marketed thrombopoietin receptor agonists(TPO-RA)approved in China,providing quantitative evidence for drug selection and therapeutic decision-making in medical institutions.METHODS Relevant data on Romiplostim for injection,Eltrombopag olamine tablets,Herombopag olamine tablets,Avatrombopag maleate tablets,and Lusutrombopag tablets were collected.Based on the Chinese Rapid Guide for Drug Evaluation and Selection in Medical Institutions(Second Edition),12 formulations of these five TPO-RA were scored quantitatively and comparatively across five dimensions:pharmacological characteristics,efficacy,safety,cost-effectiveness,and other attributes.RESULTS The comprehensive scores of the 12 formulations ranged from 62.56 to 75.50 points,with most scoring≥70 points.Using the highest-scoring formulation for each generic name as a representative,the overall rankings of the five TPO-RA were as follows:Lusutrombopag tablets(75.50 points),Eltrombopag olamine tablets(75.10 points),Avatrombopag maleate tablets(70.40 points),Romiplostim for injection(63.93 points),and Herombopag olamine tablets(63.52 points).Lusutrombopag tablets scored relatively high in pharmacological characteristics,safety,and cost-effectiveness,while Eltrombopag olamine tablets performed well in efficacy and cost-effectiveness.The other formulations showed varying scores across evaluation dimensions.CONCLUSIONS The five TPO-RA demonstrate favorable overall clinical value,with Lusutrombopag tablets and Eltrombopag olamine tablets ranking higher in comprehensive scores,these two drugs should be prioritized in drug selection and formula optimization by medical institutions.关键词
血小板生成素受体激动剂/艾曲泊帕乙醇胺片/芦曲泊帕片/药物遴选/综合评价Key words
thrombopoietin receptor agonists/Eltrombopag olamine tablets/Lusutrombopag tablets/drug selection/comprehensive evaluation分类
医药卫生引用本文复制引用
张运瑾,吴晓蓉,黄志云,张美燕,张帆,刘洪涛..我国5种上市血小板生成素受体激动剂的临床综合评价[J].中国药房,2026,37(2):142-148,7.基金项目
河北省自然科学基金项目(No.H2022307031) （No.H2022307031）
